Zanzalintinib for advanced sarcomas
Treatments studied
Part of Bones, joints & muscles, Cancer clinical trials.
This trial tests a new targeted therapy pill (XL092, also called zanzalintinib) for people with certain advanced sarcomas that have not responded to other treatments. The goal is to see if the drug shrinks tumors or slows their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (18 years or older).
- You have one of these sarcomas that has spread or cannot be surgically removed: leiomyosarcoma, bone sarcoma, or translocation-associated soft tissue sarcoma.
- For leiomyosarcoma, you must have had at least 2 prior cancer treatments. For bone sarcoma or TAS, at least 1 prior treatment is needed. Fewer than 3 of those can be from a class called tyrosine kinase inhibitors (a type of targeted therapy).
- Your cancer must be measurable on scans (like CT or MRI).
- You need to be in generally good health, with adequate blood counts, liver, kidney, and heart function. Specific blood test thresholds apply.
- You cannot have had certain types of recent treatments, uncontrolled heart disease, bleeding issues, or certain infections. Also, women who are pregnant or breastfeeding cannot join.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called zanzalintinib for people with advanced liver cancer (HCC) that can't be treated with surgery. You may join if your cancer has gotten worse after at least one prior treatment, or you couldn't tolerate that treatment.
This trial tests a new drug, zanzalintinib, in men with a fast-growing type of prostate cancer that has spread and stopped responding to standard hormone therapies. It aims to see if the drug can help shrink tumors or slow the disease.
This trial tests a new three-drug combination for advanced head and neck cancer that cannot be cured by local treatments. It aims to find the best dose of a targeted therapy called Zanzalintinib when given with two standard immunotherapy and targeted drugs.
This trial tests a new drug called zanzalintinib for people with advanced or metastatic bone sarcomas that have not responded to standard treatments. It aims to see if the drug can help shrink or slow the growth of these tumors.
This trial is looking at whether a new combination of two drugs, zanzalintinib and pembrolizumab, can help people with certain types of advanced soft-tissue sarcoma that have not responded to other treatments. It aims to find out if the combination is safe and effective.
This trial tests a combination of two drugs, zanzalintinib and eribulin, for people with advanced leiomyosarcoma or liposarcoma that has progressed after prior treatment. The goal is to see if this combination can help shrink or slow the growth of these sarcomas.
Hear when a new Metastatic Leiomyosarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.